Subsidiary | Jurisdiction | ||||||||||
Artivion Chile SpA | Chile | ||||||||||
Artivion Colombia SAS | Colombia | ||||||||||
Artivion Cyprus Limited | Cyprus | ||||||||||
Artivion EMEA GmbH | Germany | ||||||||||
Artivion France S.A.S. | France | ||||||||||
Artivion Hellas Single Member Ltd. | Greece | ||||||||||
Artivion Hong Kong, Limited | Hong Kong | ||||||||||
Artivion India Private Limited | India | ||||||||||
Artivion Italy s.r.l. | Italy | ||||||||||
Artivion LATAM Holdings Spain, SLU | Spain | ||||||||||
Artivion Malaysia, Sdn. Bhd. | Malaysia | ||||||||||
| Artivion México, S.A. de C.V. | Mexico | ||||||||||
Artivion New Zealand | New Zealand | ||||||||||
Artivion Polska Sp. z.o.o. | Poland | ||||||||||
| Artivion Spain, s.r.l. | Spain | ||||||||||
Artivion Taiwan Co. Limited | Taiwan | ||||||||||
Artivion UK Ltd. | England and Wales | ||||||||||
Ascyrus Medical GmbH | Germany | ||||||||||
Ascyrus Medical LLC | Florida | ||||||||||
AuraZyme Pharmaceuticals, Inc. | Florida | ||||||||||
CryoLife Asia Pacific, PTE. Ltd | Singapore | ||||||||||
CryoLife Beijing Medical Device Ltd. | China | ||||||||||
CryoLife Canada, Inc. | Canada | ||||||||||
CryoLife Germany HoldCo GmbH | Germany | ||||||||||
CryoLife Germany TopCo GmbH | Germany | ||||||||||
CryoLife International, Inc. | Florida | ||||||||||
CryoLife Korea Co., Ltd. | Korea | ||||||||||
CryoLife Medical (Australia) Co. Pty, Ltd. | Australia | ||||||||||
CryoLife Medical (Thailand) Co., Ltd. | Thailand | ||||||||||
CryoLife Vietnam Co., Ltd. | Vietnam | ||||||||||
Jolly Buyer Acquisition GmbH | Switzerland | ||||||||||
JOTEC do Brasil Ltda. | Brazil | ||||||||||
JOTEC GmbH | Germany | ||||||||||
JOTEC Sales GmbH | Switzerland | ||||||||||
JOTEC UK Ltd. | England | ||||||||||
On-X Life Technologies Holdings, Inc. | Delaware | ||||||||||
On-X Life Technologies, Inc. | Delaware | ||||||||||
Valve Special Purpose Co., LLC | Delaware | ||||||||||
Artivion Inc — 10-K exhibit
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.